Moderna’s COVID-19 vaccine shows efficacy of 94.5% in Phase 3 trial
Moderna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read moreModerna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read moreGovernments around the world are scrambling to prepare for the rollout of the Pfizer and BioNTech COVID-19 vaccine, with many
Read morePfizer and BioNTech announced this week that they have reached an agreement with the European Commission to supply 200 million
Read morePfizer and BioNTech have announced their mRNA-based vaccine candidate for COVID-19, tested in a Phase 3 study involving 43,538 participants,
Read moreNovavax has announced the expansion of its Gaithersburg, Maryland campus to support global vaccine development through the addition of two
Read moreSanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreEli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreAstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read moreSYNLAB, leading European provider of medical diagnostic solutions, has revealed the successful authorization of saliva sampling platform, another groundbreaking non-invasive
Read moreViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read more